NASDAQ:FUSN

Fusion Pharmaceuticals Competitors

$9.51
-0.61 (-6.03 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$9.50
Now: $9.51
$10.08
50-Day Range
$9.75
MA: $11.26
$12.15
52-Week Range
$9.31
Now: $9.51
$19.00
Volume42,176 shs
Average Volume54,632 shs
Market Capitalization$397.95 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Fusion Pharmaceuticals (NASDAQ:FUSN) Vs. SGMO, KRYS, IMVT, ALVR, KYMR, and RGNX

Should you be buying FUSN stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to Fusion Pharmaceuticals, including Sangamo Therapeutics (SGMO), Krystal Biotech (KRYS), Immunovant (IMVT), AlloVir (ALVR), Kymera Therapeutics (KYMR), and REGENXBIO (RGNX).

Fusion Pharmaceuticals (NASDAQ:FUSN) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 57.7% of Sangamo Therapeutics shares are owned by institutional investors. 1.8% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and Sangamo Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion PharmaceuticalsN/AN/A$-16,190,000.00N/AN/A
Sangamo Therapeutics$102.43 million15.46$-95,190,000.00($0.85)-12.96

Fusion Pharmaceuticals has higher earnings, but lower revenue than Sangamo Therapeutics.

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and Sangamo Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fusion Pharmaceuticals00503.00
Sangamo Therapeutics02402.67

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. Sangamo Therapeutics has a consensus price target of $20.20, indicating a potential upside of 83.30%. Given Fusion Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than Sangamo Therapeutics.

Profitability

This table compares Fusion Pharmaceuticals and Sangamo Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fusion PharmaceuticalsN/A-26.14%-18.26%
Sangamo Therapeutics-51.51%-16.32%-9.85%

Summary

Fusion Pharmaceuticals beats Sangamo Therapeutics on 6 of the 10 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and Krystal Biotech (NASDAQ:KRYS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 73.1% of Krystal Biotech shares are owned by institutional investors. 27.4% of Krystal Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and Krystal Biotech's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion PharmaceuticalsN/AN/A$-16,190,000.00N/AN/A
Krystal BiotechN/AN/A$-19,090,000.00($1.20)-57.74

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and Krystal Biotech, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fusion Pharmaceuticals00503.00
Krystal Biotech00603.00

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. Krystal Biotech has a consensus price target of $101.00, indicating a potential upside of 45.76%. Given Fusion Pharmaceuticals' higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than Krystal Biotech.

Profitability

This table compares Fusion Pharmaceuticals and Krystal Biotech's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fusion PharmaceuticalsN/A-26.14%-18.26%
Krystal BiotechN/A-10.72%-10.40%

Summary

Krystal Biotech beats Fusion Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and Immunovant (NASDAQ:IMVT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 40.2% of Immunovant shares are owned by institutional investors. 0.2% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and Immunovant's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion PharmaceuticalsN/AN/A$-16,190,000.00N/AN/A
ImmunovantN/AN/A$-66,390,000.00($1.54)-10.18

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and Immunovant, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fusion Pharmaceuticals00503.00
Immunovant011402.93

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. Immunovant has a consensus price target of $45.60, indicating a potential upside of 190.82%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than Fusion Pharmaceuticals.

Profitability

This table compares Fusion Pharmaceuticals and Immunovant's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fusion PharmaceuticalsN/A-26.14%-18.26%
ImmunovantN/A-34.80%-32.38%

Summary

Fusion Pharmaceuticals beats Immunovant on 5 of the 8 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 32.1% of AlloVir shares are owned by institutional investors. 1.0% of AlloVir shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and AlloVir's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion PharmaceuticalsN/AN/A$-16,190,000.00N/AN/A
AlloVirN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and AlloVir, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fusion Pharmaceuticals00503.00
AlloVir00403.00

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. AlloVir has a consensus price target of $48.75, indicating a potential upside of 110.04%. Given Fusion Pharmaceuticals' higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than AlloVir.

Profitability

This table compares Fusion Pharmaceuticals and AlloVir's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fusion PharmaceuticalsN/A-26.14%-18.26%
AlloVirN/AN/AN/A

Fusion Pharmaceuticals (NASDAQ:FUSN) and Kymera Therapeutics (NASDAQ:KYMR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 37.8% of Kymera Therapeutics shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and Kymera Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion PharmaceuticalsN/AN/A$-16,190,000.00N/AN/A
Kymera TherapeuticsN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and Kymera Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fusion Pharmaceuticals00503.00
Kymera Therapeutics02402.67

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. Kymera Therapeutics has a consensus price target of $48.6667, indicating a potential upside of 45.53%. Given Fusion Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than Kymera Therapeutics.

Profitability

This table compares Fusion Pharmaceuticals and Kymera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fusion PharmaceuticalsN/A-26.14%-18.26%
Kymera TherapeuticsN/AN/AN/A

Summary

Fusion Pharmaceuticals beats Kymera Therapeutics on 4 of the 6 factors compared between the two stocks.

Fusion Pharmaceuticals (NASDAQ:FUSN) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, earnings and dividends.

Institutional & Insider Ownership

61.4% of Fusion Pharmaceuticals shares are owned by institutional investors. Comparatively, 75.2% of REGENXBIO shares are owned by institutional investors. 14.1% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Fusion Pharmaceuticals and REGENXBIO's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion PharmaceuticalsN/AN/A$-16,190,000.00N/AN/A
REGENXBIO$35.23 million42.43$-94,730,000.00($3.26)-10.79

Fusion Pharmaceuticals has higher earnings, but lower revenue than REGENXBIO.

Analyst Recommendations

This is a summary of recent recommendations for Fusion Pharmaceuticals and REGENXBIO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fusion Pharmaceuticals00503.00
REGENXBIO02512.88

Fusion Pharmaceuticals currently has a consensus price target of $23.6667, indicating a potential upside of 148.86%. REGENXBIO has a consensus price target of $62.50, indicating a potential upside of 77.71%. Given Fusion Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Fusion Pharmaceuticals is more favorable than REGENXBIO.

Profitability

This table compares Fusion Pharmaceuticals and REGENXBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fusion PharmaceuticalsN/A-26.14%-18.26%
REGENXBIO-63.13%-21.73%-18.74%


Fusion Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.02-2.1%$1.58 billion$102.43 million-18.37Analyst Upgrade
Gap Down
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$69.29-6.8%$1.54 billionN/A-46.82News Coverage
Gap Down
Immunovant logo
IMVT
Immunovant
1.8$15.68-1.4%$1.54 billionN/A-12.16Unusual Options Activity
News Coverage
AlloVir logo
ALVR
AlloVir
1.4$23.21-5.2%$1.51 billionN/A0.00Gap Down
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.2$33.44-4.6%$1.50 billionN/A0.00News Coverage
Gap Down
REGENXBIO logo
RGNX
REGENXBIO
1.6$35.17-0.0%$1.49 billion$35.23 million-14.18News Coverage
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.66-3.2%$1.41 billionN/A0.00Insider Selling
High Trading Volume
News Coverage
Gap Down
Replimune Group logo
REPL
Replimune Group
1.5$30.07-1.9%$1.40 billionN/A-16.99
Alector logo
ALEC
Alector
1.3$17.37-13.0%$1.38 billion$21.22 million-7.79Insider Selling
Gap Down
Ocugen logo
OCGN
Ocugen
1.1$6.96-0.7%$1.31 billionN/A-4.70Gap Up
Translate Bio logo
TBIO
Translate Bio
1.6$17.26-2.1%$1.30 billion$7.80 million-16.13
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.77-3.1%$1.15 billionN/A-2.98Gap Down
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$27.90-0.9%$1.15 billion$100.56 million0.00
Mesoblast logo
MESO
Mesoblast
1.4$8.51-0.6%$1.10 billion$32.16 million-9.67Analyst Upgrade
News Coverage
Curis logo
CRIS
Curis
1.3$11.50-2.9%$1.05 billion$10 million-14.02Gap Down
Vaxcyte logo
PCVX
Vaxcyte
1.7$20.22-2.7%$1.04 billionN/A0.00
Scholar Rock logo
SRRK
Scholar Rock
1.5$29.94-6.2%$1.03 billion$20.49 million-12.42Gap Down
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$13.95-1.1%$1.02 billion$356.07 million6.84
Cortexyme logo
CRTX
Cortexyme
1.3$33.59-6.9%$992.65 millionN/A-14.00Gap Down
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.10-5.8%$922.43 million$42.74 million-223.33Gap Down
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$24.63-0.9%$890.08 millionN/A-4.07
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.7$9.08-6.9%$887.99 million$250,000.00-7.15News Coverage
Gap Down
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$18.83-0.7%$883.45 million$69.89 million-4.49
Passage Bio logo
PASG
Passage Bio
1.8$16.34-4.4%$879.60 millionN/A0.00News Coverage
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.92-1.6%$852.18 million$22.99 million-10.60News Coverage
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$22.02-2.8%$839.78 millionN/A-9.10News Coverage
Gap Down
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.73-3.7%$832.47 million$2.51 million-4.08Gap Down
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.47-5.4%$818.93 millionN/A0.00Lockup Expiration
Gap Up
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$21.19-6.0%$800.16 millionN/A0.00Gap Up
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$5.05-1.6%$785.11 million$1.12 million-5.10
Inhibrx logo
INBX
Inhibrx
1.6$20.50-0.4%$773.83 millionN/A0.00
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$22.67-0.3%$734.76 million$5.78 million-10.64
Athira Pharma logo
ATHA
Athira Pharma
2.2$19.08-2.3%$708.25 millionN/A0.00Analyst Upgrade
News Coverage
Gap Up
Vaxart logo
VXRT
Vaxart
1.3$5.53-2.5%$651.25 million$9.86 million-9.37Gap Down
DBV Technologies logo
DBVT
DBV Technologies
1.2$5.74-3.3%$630.67 million$14.75 million-2.46
MeiraGTx logo
MGTX
MeiraGTx
1.4$13.35-3.3%$590.92 million$13.29 million-9.47News Coverage
Gap Down
Tarsus Pharmaceuticals logo
TARS
Tarsus Pharmaceuticals
1.5$28.56-1.2%$585.57 millionN/A0.00Analyst Downgrade
Lockup Expiration
Compugen logo
CGEN
Compugen
1.4$8.42-0.0%$576.10 million$17.80 million-22.76Analyst Report
Analyst Revision
Agenus logo
AGEN
Agenus
1.6$2.79-0.0%$570.05 million$150.05 million-2.56
Solid Biosciences logo
SLDB
Solid Biosciences
1.8$5.21-3.1%$556.83 millionN/A-2.53Gap Down
Poseida Therapeutics logo
PSTX
Poseida Therapeutics
1.8$8.90-0.6%$552.76 millionN/A-1.30Gap Down
Oyster Point Pharma logo
OYST
Oyster Point Pharma
1.0$20.48-2.5%$530.64 millionN/A-5.90Gap Down
Precision BioSciences logo
DTIL
Precision BioSciences
1.5$8.60-3.6%$490.08 million$22.24 million-4.28Gap Down
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$13.23-5.1%$474.60 millionN/A0.00Analyst Report
Gap Down
AVROBIO logo
AVRO
AVROBIO
1.7$11.32-2.5%$471.16 millionN/A-3.43News Coverage
Gap Down
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.25-1.5%$466.41 millionN/A-8.20
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$9.10-1.4%$445.46 million$4.36 million-3.18Analyst Upgrade
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.78-6.6%$443.95 million$147.87 million-3.25News Coverage
Gap Down
Opthea logo
OPT
Opthea
1.5$9.66-1.2%$419.80 millionN/A0.00Lockup Expiration
News Coverage
Gap Down
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$13.66-1.0%$380.70 millionN/A0.00
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.